Enregistrement - Lobbyistes salariés d'entreprises

Objets

• Commerce intérieur
• Développement économique
• Emploi et formation
• Industrie
• Propriété intellectuelle
• Recherche et développement
• Santé
• Sciences et technologies

Détails sur l'objet

Politique ou Programme

• Biologics and Genetic Therapies Directorate as it relates to policies affecting the review and approval of submissions
• Clinical Trials environment in Canada: operational issues, investment, enrollment
• Economic Growth Initiatives as it relates to pharmaceutical, clinical trials investment, life sciences industry
• Innovation Agenda - as it relates to the Life Science Industry and the Federal Initiative lead by Innovation, Science, Economic Development
• National Pharmaceutical Strategy and negotiation of the Health Accord, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing.
• Pandemic Planning as it relates to the Task Group on Antiviral Prophylaxis recommendations
• Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions
• Policies related to rare disease as it relates to separate regulatory pathway for drugs for rare diseases and government strategies.
• Policies related to the importation of pharmaceuticals from Canada to the United States

Politique ou Programme, Règlement

• Orphan Drug Regulatory Framework as it relates to separate regulatory pathway for drugs for rare diseases

Proposition législative, Projet de loi ou résolution

• Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection
• Food and Drugs Act Modernization initiative as it relates to reform of drug submission review and approval process
• Food and Drugs Act and Regulations, as they relate to drug export and cross-border trade
• Food and Drugs Act and Regulations, as they relate to the establishment of an approval framework for subsequent entry biologic products
• Food and Drugs Act and Regulations, as they relate to the provision of data exclusivity for innovative drug products
• Food and Drugs Act and Regulations, as they relate to the review and approval of new drug submissions and post market surveillance of drug products
• House of Commons Standing Committee of Health's (HESA) as it relates to Pharmacare, rare disease and/or any other pertinent legislative proposal before the committee
• Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal
• Patent Act as it relates to changes affecting term restoration or Canada's Access to Medicines Regime
• Patented Medicines Prices Review Board (PMPRB), as it relates to reporting requirements, pricing guidelines, and dispute resolution
• United States, Mexico, Canada Agreement (USMCA) and pharmaceutical intellectual property protection.

Règlement

• Health Canada/PMPRB proposed regulation changes to the Patented Medicines Regulations.

Subvention, Contribution ou autre avantage financier

• Strategic Innovation Fund, as it relates to any initiative submitted or supported.

Techniques de communication

• Communication écrite
• Communication orale

Institutions gouvernementales

• Affaires mondiales Canada (AMC)
• Agence de la santé publique du Canada (ASPC)
• Agence fédérale de développement économique pour le Sud de l'Ontario (FedDev)
• Bureau du Conseil privé (BCP)
• Cabinet du Premier ministre (CPM)
• Chambre des communes
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Environnement et Changement climatique Canada (ECCC)
• Finances Canada (FIN)
• Innovation, Sciences et Développement économique Canada (ISDE)
• Instituts de recherche en santé du Canada (IRSC)
• Santé Canada (SC)
• Secrétariat du Conseil du Trésor du Canada (SCT)
• Sénat du Canada

Adresse :
7070 Mississauga Road
Mississauga, ON  L5N 5M8
Canada

Numéro de téléphone : 905-542-5555
Numéro de fax : 905-542-5689  

Renseignements sur la société mère